Loading
A phase 2 trial of tislelizumab in pancreatic cancer, run by Ruijin Hospital, not yet recruiting.
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC is a phase 2, interventional study registered as NCT06573398 by Ruijin Hospital, with a registry enrolment figure of 20 participants, started 2024-09-01 and due to reach its primary completion in 2025-09-01. Interventions recorded: SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin. Conditions listed: Carcinoma, Pancreatic Ductal. Primary outcome: R0 resection rate. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of ductal adenocarcinoma of pancreas;". No results are recorded here; the registry entry is the source.
Shares Borderline resectable pancreatic ductal adenocarcinoma, SBRT / SABR (stereotactic radiotherapy), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, SBRT / SABR (stereotactic radiotherapy), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares SBRT / SABR (stereotactic radiotherapy), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Borderline resectable pancreatic ductal adenocarcinoma, SBRT / SABR (stereotactic radiotherapy), Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.